Coherus Oncology, Inc. - Common Stock (CHRS)

With less than 12 months of cash on hand, the margin for error is thin, and the oncologist survey on LOQTORZI's standard-of-care status may matter as much as any cost cut.

Coherus cuts 30% of staff and narrows focus to esophageal cancer as cash runway tightens.

Coherus Oncology (NASDAQ:CHRS) plans to cut approximately 30% of its workforce and focus development of its experimental drug tagmokitug on esophageal cancer as it seeks to reduce spending and grow sales of its cancer treatment LOQTORZI. On its third-quarter 2026 earnings call, management said the

Coherus Oncology (NASDAQ:CHRS) presented interim clinical data for tagmokitug, an investigational therapy designed to target CCR8-positive regulatory T cells, in several solid-tumor settings. The company highlighted early activity in esophageal squamous cell carcinoma, or ESCC, and said it plans to

LOQTORZI sales surged 37% year-over-year as clinical programs advance toward key data readouts.

Coherus Oncology (NASDAQ:CHRS) said it is approaching several clinical data disclosures in the second half of 2026, while reporting continued growth for its LOQTORZI treatment and lower operating expenses following the divestiture of its UDENYCA franchise. Chief Executive Officer Denny Lanfear said

Coherus Oncology (NASDAQ:CHRS) said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data readouts across its oncology pipeline later this year. On the company’s first-quarter 2026 earnings call

CHRS Q1 2026 Earnings Transcript

4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.

The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today.